Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report

    Lina María Saldarriaga Rivera, Christian David Marín Giraldo, Fabián Andrés Hernández Velasco
    TLDR Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
    This case report discusses a 24-year-old female patient with alopecia areata (AA) who experienced extensive hair loss over four years, unresponsive to various treatments including minoxidil, clobetasol, oral and intralesional corticosteroids, finasteride, and cryotherapy. The study highlights the significant emotional and social impact of AA and the challenges in managing resistant cases. It presents the first reported successful use of the JAK inhibitor tofacitinib in a patient with AA in Colombia, suggesting its potential as an effective treatment option for difficult-to-control AA. Ethical considerations were adhered to, with informed consent obtained, and no conflicts of interest or funding were reported.
    Discuss this study in the Community →

    Cited in this study

    11 / 11 results

    Related

    4 / 4 results